Warner Biddle and Christi Shaw, two prominent former executives at Gilead’s CAR-T division, will try to turn around an autoimmune cell therapy developer that’s lost most of its value since raising ...

Next-generation sequencing (NGS) is the future of GxP for biosafety and product characterization. This method of fast, sensitive, cost-efficient genetic sequencing can help evaluate viral content, ...

Final follow-up results suggest Opdivo and Yervoy could be close to a cure for some people with advanced melanoma, shifting how doctors administer follow-up care.

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

Three drug startups collectively raised more than $700 million in initial public offerings Thursday, a flurry of activity after a largely fallow summer in which few biotechnology companies made the ...

Today, a brief rundown of news from Roche and Gilead Sciences, as well as updates from Eli Lilly, Biogen and GSK that you may have missed. Multibillion-dollar buyouts from Bristol Myers Squibb and ...

Months after winning approval of a new vaccine for respiratory syncytial virus, Moderna is acknowledging that wresting market share from its two competitors may be more difficult than it thought.

FSHD, or facioscapulohumeral muscular dystrophy, is a neuromuscular disorder characterized by muscle weakness in the face, shoulders and arms. It’s primarily caused ...